This activity was planned for clinicians to be able to select guideline-driven antiarrhythmic drugs (AADs) in specific cases of atrial fibrillation (AF), recognizing safe medication considerations. It is part of the Early Onset of Atrial Fibrillation & the Contemporary Use of Antiarrhythmic Drugs.
Learner Objectives
Upon completion of this activity, you should be able to:
- Employ patient safety principles in AF management, particularly in assessing and minimizing risks associated with antiarrhythmic drug use.
Target Audience
The primary target audience is general cardiologists and electrophysiologists, as well as other members of the CV team including nurse practitioners, physician assistants and pharmacists. In addition, general practitioners and other specialists who manage AF patients will benefit from the education and will be provided with opportunities to access the education.
Important Dates
Date of Release: October 31,2024
Term of Approval/Date of Expiration: November 3, 2025
Faculty
Andrea M. Russo, MD, FACC
Cooper University Health Care
Voorhees Township, NJ
Disclosure:
Consultant Fees/Honoraria: Abbott, Atricure, Bayer Healthcare Pharmaceuticals, Biosense Webster, Biotronik, BMS/Pfizer, Boston Scientific, Medtronic, Orchestra Biomed, Pacemate, Sanofi
Acknowledgement
Educational grant support provided by: Sanofi